Tuvusertib

N/A

Report date: 2026/03/20 20:03:07
NME

Base Information

Drug NameTuvusertib
Drug Alias NameM-1774MSC2584415AVRT-1363004VXc-400
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine-protein kinase ATR inhibitors
TargetsSerine-protein kinase ATR
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisProstatic Neoplasms, Castration-Resistant +[17] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[18] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesEmd Serono IncMerck Serono
China Registration ClassN/A

Develop Information

Active CompaniesMerck Healthcare Kgaa, Darmstadt, Germany, An Affiliate Of Merck Kgaa, Darmstadt, GermanyEmd Serono IncEmd Serono Research & Development Institute Inc +[10] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm MetastasisProstatic Neoplasms, Castration-Resistant +[16] 
Inactive IndicationsCarcinoma, Transitional Cell

Other Information

ATC CodeN/A
Related LinksN/A